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Abstract 
The combination of positron emission tomography (PET) scanners and x-ray computed tomography (CT) scanners into a 
single PET/CT scanner has resulted in significant improvements in the diagnosis and staging of disease, particularly in the 
field of oncology. A decade on from the publication of the details of the first PET/CT scanner, we review the technology 
and applications of the modality. We examine the design aspects of combining two different imaging types into a single 
scanner, and the artefacts produced such as attenuation correction, motion and CT truncation artefacts. The article also 
provides a discussion and literature review of the applications of PET/CT to date, covering detection of tumours, 
radiotherapy treatment planning, patient management, and applications external to the field of oncology. 
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Introduction  
 
Multimodality imaging in medicine aims to exploit the 
complementary features of different medical imaging 
devices to provide physicians with an accurate tool for 
diagnosis and localisation of pathological tissue or 
assessment of tissue function. Typically, the procedure 
followed is that the patient is scanned by different devices, 
and the images from each device are then overlayed, 
resulting in a fused image. One challenge in multimodality 
imaging is the accurate co-registration of images to ensure 
that the patient’s anatomy correctly ‘lines up’ in the fused 
image. Although advanced software is available to carry 
out this task1 the patient typically needs to physically move 
from one imaging device to another. Apart from possible 
errors  due  to  patient  misalignment  between scanners, the  
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time delay between the non-simultaneous imaging sessions 
can occasionally be sufficient for changes to occur in the 
anatomy or physiology of the tissues being measured.  
One solution to the above issues is the combination of 
different imaging modalities into a single scanner capable 
of simultaneous measurements by different techniques. 
Arguably, the most successful example of this to date is the 
combination of a positron emission tomography (PET) 
scanner, which primarily measures biochemical processes, 
and an x-ray computed tomography (CT) scanner, which 
primarily measures anatomical features, into a single unit 
referred to as a PET/CT scanner.  
Although published clinical CT scans date back as 
early as 19732,3, and PET imaging even earlier (for a review 
of the history of PET the reader is directed to Muehllehner 
and Karp4), the development of a prototype PET/CT 
scanner was not reported until at least 19985,6 by a research 
group based at the University of Pittsburgh. The prototype 
scanner was a third generation Siemens Somatom AR.SP 
CT scanner placed in series with a Siemens ECAT ART 
PET scanner (Siemens Medical Solutions, Erlangen, 
Germany). The CT and PET scanners were housed in a 
single assembly with an axial separation of 60 cm such that 
the patient lay on an extended single couch which moved 
through the combined gantry. The PET and CT components 
were operated independently from separate consoles, but a 
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software tool (developed in-house) allowed fused images to 
be displayed as colour PET images superimposing 
greyscale CT images. 
In the few years since the University of Pittsburgh 
group published the details of their prototype scanner, 
PET/CT has proliferated in the medical industry. The first 
device to be made available commercially was the 
Discovery LS (GE Medical Systems, Milwaukee, WI, 
USA). This device involved simply combining their 
existing ADVANCE NXi PET scanner with a Lightspeed 
Plus 4-slice helical CT scanner and use of a newly designed 
patient bed. This system continued to operate with separate 
computers and software to control acquisition and 
processing of PET and CT respectively. Customized 
software was used for image fusion. Since 2001 a number 
of other medical equipment manufacturers have begun to 
offer PET/CT systems as a single unit or as upgrades to 
existing CT scanners. Although primarily used in 
diagnostic imaging departments, increasingly major 
radiation oncology departments have either purchased 
systems or are in the process of such purchases as an 
adjunct to radiotherapy planning. Recent advances have 
even seen micro PET/CT scanners developed for imaging 
of small animals7,8,9. 
The aim of this article is to provide a review of the 
current technology and applications of PET/CT as a 
combined imaging modality. We will review the 
technology and hardware of a PET/CT scanner and discuss 
its applications in oncology and potential applications 
outside of oncology in the current published literature. 
Extensive literature searches have been undertaken. 
However, publications included in this review do not 
include the complete body of literature available, which is 
now vast. Rather, the aim of the present work was to 
include a comprehensive selection of articles that are 
indicative of the technology and the scope of its 
applications, as well as highlight some of the potential 
limitations. 
 
 
Aspects of PET/CT technology 
 
Overview 
The following section is a brief overview of the 
technological and design aspects of combining PET and CT 
scanners into a single unit. For a detailed description of the 
physics of either PET or x-ray CT, the reader is referred to 
current radiology text-books10,11 and recent reviews such as 
Muehllehner and Karp4. For excellent reviews of 
multimodality imaging systems focusing specifically on 
technological advances in scanner design, the reader is 
referred to Townsend12 and Zanzonico13. 
 
Scanner design 
The first combined anatomical-functional imaging 
system to find widespread clinical application was not a 
PET system, but the GE Hawkeye single photon emission 
computed tomography (SPECT)/CT scanner (GE 
Healthcare, Chalfont St. Giles, UK), incorporating a low-
power x-ray tube for attenuation correction and localisation 
with a dual-headed scintillation camera. In the first 
generation PET/CT scanners there was a minimum level of 
actual hardware integration with the major vendors 
incorporating an existing high-end PET scanner with a 2 or 
4 slice CT scanner. These essentially separate components 
were housed inside a single gantry, in the case of the 
Discovery LS (based on the ADVANCE NXi, GE 
Healthcare) and Biograph (based on the ECAT ACCEL, 
Siemens Medical Solutions, Erlangen, Germany), or in two 
separate gantries, in the case of the Philips Gemini system 
(based on the Allegro, Philips Medical Systems, Best, the 
Netherlands).  The centres of the scan planes of the two 
modalities are offset axially by distances of 25 cm 
(Discovery LS) to 80 cm (Biograph and Gemini. Note: the 
Gemini allows the user to move the PET gantry to increase 
this offset, giving the potential to improve access to the 
patient during the scan). The patient handling system in 
these configurations is possibly the key mechanical 
development. The extended tunnel length of the dual gantry 
system has required a redesign allowing a greater travel 
distance without a significant increase in patient couch sag.  
Recent advances in PET/CT technology have resulted 
from improvements in the performance of the individual 
CT and PET components and improving software 
integration, but the general design concept remains 
unchanged. The desire for high-speed CT, driven by the 
cardiology market, has seen the original 2 or 4 slice 
scanners replaced with 8, 16, 40 and 64 slice models, with 
the latter capable of high temporal resolution and cardiac 
gated acquisition. Hardware developments in PET have 
concentrated on improved detection speed and efficiency. 
Time-of-flight systems are now on the market for clinical 
use, made possible because of the development of cerium 
doped lutetium oxyorthosilicate (LSO) and cerium doped 
lutetium yttrium oxyorthosilicate (LYSO) scintillator 
materials, which combine high density, high effective 
atomic number, good energy resolution (10–11%) and 
excellent timing resolution (~600 ps)14.  Time-of-flight 
reconstruction has been shown to offer improved contrast 
recovery versus noise for 18F-fluorodeoxy glucose (FDG), 
with the benefit even greater for larger patients15, leading to 
improved image quality and/or higher throughput.   
Other potential improvements in PET detector 
technology that are currently in the research stage include 
double-layer “phoswich” crystal blocks that allow the 
depth-of-interaction to be measured16, thereby improving 
spatial resolution; and the replacement of photomultipliers 
for avalanche photodiodes17, which can be integrated into 
hybrid PET/Magnetic Resonance Imaging (MRI) systems18. 
Single detector arrays suitable for implementation in an 
integrated PET/SPECT system have also been proposed19. 
 
Attenuation correction 
One of the physical advantages of hybrid PET/CT 
scanners is that the intrinsically coregistered CT data can be 
used for PET attenuation correction. For this reason the 
PET scanners no longer require separate transmission 
sources and overall scan times can be markedly reduced by 
eliminating the need for a separate transmission scan. The 
option to include a transmission source might still be useful 
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in special cases where radiation dose to the patient is of 
particular concern, such as for paediatric patients or 
volunteers participating in drug trials. However, for the 
majority of clinical examinations, particularly in oncology, 
automatic tube current modulation algorithms20,21 can be 
used to minimise radiation doses and still provide sufficient 
statistical quality for robust attenuation correction as well 
as anatomical correlation. Accordingly, a transmission 
source is not often required and so most PET/CT scanners 
are now supplied without one. 
When performing a PET attenuation correction using 
CT data, it is important to take account of the fact that 
linear attenuation is energy dependent and the CT scan uses 
a spectrum of x-rays from 40 to 140 keV, whereas PET 
imaging utilises monoenergetic 511 keV photons. It is 
therefore necessary to scale the CT derived attenuation to 
the appropriate energy. At the annihilation photon energy of 
511 keV the dominant process is Compton scattering. 
However, in the CT energy range the main attenuation 
contribution in bone is from photoelectric absorption. There 
is no simple function for mapping Hounsfield units to linear 
attenuation coefficients at 511 keV that is generally valid 
for all materials. 
As Kinahan et al22 suggest, a dual-energy CT scan 
allows extraction of the individual photoelectric and 
Compton contributions of the attenuation. However, this 
unnecessarily increases the patient dose when other, 
simpler methods of correction are available. One such 
approach is the segmentation method, which replaces the 
CT-number in the reconstructed image with an attenuation 
value at 511 keV corresponding to the type of tissue22,23. 
One drawback of this method is that the density of some 
tissue types varies considerably and will not be represented 
accurately by a discrete value. An alternative method is a 
scaling approach in which the entire CT image is multiplied 
by the ratio of attenuation coefficients of water 
(representing soft tissues) at the photon energies of CT and 
PET. An effective energy for CT is typically selected as 70 
keV23,24. This method assumes a constant ratio between 
attenuation coefficients at different energies. However, this 
is a poor approximation for bone and hence a bilinear or 
hybrid approach can be adopted25.  In the bilinear method a 
different scaling factor is applied to CT-numbers depending 
on a threshold which is chosen between 0 and 100 
Hounsfield units. This method implicitly assumes that all 
materials in the body can be described as linear mixtures of 
air and water, or water and bone. The hybrid method 
integrates both segmentation and scaling by first estimating 
the attenuation map at 511 keV by separating out the tissue 
types based on CT-number and then using separate scaling 
factors for bone and non-bone components. The use of a 
simple segmentation into bone and non-bone avoids 
difficulties that may be encountered by tissue 
misclassification in more complex segmentations. 
 
Scatter correction 
Although more sensitive than their 2D counterpart, 
fully 3D PET scanners (having no interslice septa) are more 
susceptible to Compton scattered photons, which typically 
contribute up to 50% of the detected events. Hence, 
effective and reliable scatter correction is necessary. 
Modern scanners use sophisticated algorithms to estimate 
and subtract the single-scatter component in the raw data as 
part of the reconstruction process. This is done by 
estimating the activity distribution from a low-quality non-
scatter-corrected PET image, estimating the Klein-Nishina 
cross section from the CT image and calculating the 
expected Compton scatter distribution26,27. A smaller 
contribution can be attributed to photons that have 
undergone multiple scattering. These are modelled in some 
scatter correction methods28,29, although some of these 
photons will have lost sufficient energy and will be 
adequately rejected by energy windowing. 
 
Artefacts 
With combined PET/CT imaging, artefacts from the 
CT-based attenuation correction of the PET image can be 
encountered and are in addition to those artefacts common 
to independent PET and CT imaging. A major concern is 
the propagation of CT artefacts into the corrected PET 
image. Inaccurate attenuation correction may cause under 
or over-correction, which is particularly evident as a result 
of metallic implants in the body. Radiodense spots apparent 
on the corrected PET image can be mistaken for 
malignancies or obscure real tumours. A comparison with 
the uncorrected PET image is necessary for accurate 
interpretation30,31 or a metal-artefact reduction method may 
be used32,33. 
CT contrast material may also contribute similar over-
corrections to the PET image. Carney et al34 have suggested 
a modification in which contrast-enhanced CT pixels can be 
separated from those containing bone for oral contrast 
studies and Nehmeh et al35 similarly propose a segmented 
contrast correction. Antoch et al36 have shown that a 
negative oral contrast agent, mannitol (2.5%) and locust 
bean gum (0.2%) dissolved in water (mannitol-LBG), 
prevents attenuation artefacts due to its water-based nature. 
In the case of intravenous contrast, Yau et al37 have 
concluded that it is feasible to incorporate contrast into 
routine PET/CT protocols and their study demonstrates no 
clinical or statistical difference from non-contrast imaging. 
Similarly, Berthelsen et al38 reported no contrast-introduced 
artefacts or changes in clinical diagnostic interpretation.  
Misregistration between the CT and PET images can 
occur from different motion artefacts. The advantage of 
PET/CT is that patient movement is considerably limited to 
translation of the bed through the scanner. Some 
mechanical misalignment can occur from the sequential 
data acquisition, however, the primary cause of artefact is 
due to respiratory motion of the patient31. The CT scan is 
typically acquired during deep inspiration breath-hold, 
whereas the PET image is obtained during free tidal 
breathing due to the length of the scan.  Different breathing 
protocols can be implemented to counter this problem6 
although misalignment of the images may still occur. 
During normal tidal volume breathing more time is spent in 
end-expiration than end-inspiration and hence the majority 
of counts arising from organs close to the diaphragm will 
be acquired in the position of those organs when the lungs 
are at their smallest volume. However, to obtain better 
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anatomical detail of the lung parenchyma, most CT 
acquisition protocols require lung expansion. Accordingly, 
the position of the diaphragm is generally lower on the CT 
than the average position of the dome of the liver on the 
PET images, where true counts are also misrepresented due 
to the effect of temporal blurring. The combination of this 
respiration-related undersampling plus the application of 
attenuation correction coefficients appropriate to lung 
rather than soft tissue generally leads to under-correction of 
true counts from the dome of the liver and frequently has 
the appearance of a relatively photopenic banana-shaped 
region at the lung base.  Motion of internal organs during 
respiration can cause focal FDG uptake in the dome of the 
liver to appear to be located in the lower lung field23,39. 
Consequently, accuracy of lesion localisation in the 
diaphragmatic region may be limited and semi-quantitative 
assessment of the intensity of lesions in this region is 
compromised by the combination of respiratory blurring 
and incorrect attenuation correction. 
The transverse field-of-view (FOV) of the PET image 
is typically larger than that of the CT scan and this can 
introduce a transaxial truncation artefact40. However, 
Kinahan et al22 state that the effects on the PET emission 
image are generally smaller than expected, particularly if an 
iterative transmission reconstruction algorithm is used to 
reconstruct the missing CT data. Beyer et al40 also discuss 
the effect of these truncation artefacts for larger patients 
where PET activity can be underestimated by up to 90% in 
the truncation area. They propose the use of a retrospective 
algorithm using an extended field-of-view correction, 
which considerably improves accuracy of the final image.  
 
 
Clinical applications and patient management 
 
Overview 
The value of PET/CT using FDG for diagnosis and 
staging is beyond doubt for a wide range of clinical sites. In 
their systematic review Gambhir and colleagues41 
estimated, across all applications, that 30% of patients 
undergo a change in management as a result of an FDG 
PET scan (based on 1565 patients). By far, the most 
intensive use of FDG PET/CT to date has been as a 
diagnostic and staging device in oncology. Czernin et al42 
have recently provided a valuable review of literature for 
cancer staging using PET/CT and conclude that there is 
reliable evidence of its diagnostic advantage for major 
cancers.  
The following section provides a brief overview of a 
broad range of recent clinical studies in which FDG 
PET/CT has been employed. Table 1 summarises pertinent 
data from various studies, indicating the use and efficacy of 
FDG PET/CT for different tumour sites.  In the following 
sections PET/CT and PET refers to the use of FDG and not 
other radiotracers unless specified. 
 
Small and non-small cell lung cancer 
Lardinois and co-workers43 compared the diagnostic 
accuracy of integrated PET/CT with PET alone, CT alone 
and PET and CT viewed side by side for patients with non-
small cell lung cancer (NSCLC). They prospectively 
compared the results from the four imaging modalities in 
50 patients and found that PET/CT provided additional 
information in 41% of the cases compared with PET and 
CT viewed side by side43. The additional information is 
useful for more accurate localisation of lymph nodes, chest 
wall infiltration, atelectasis and peritumoral inflammation. 
Bar-Shalom et al44 also note that additional information is 
provided by PET/CT in 49% of cases (64 of 204 patients 
with lung cancer), although in their study only 14% led to a 
change in management. A further study by Antoch and co-
workers45 compared contrast enhanced PET/CT with PET 
and contrast enhanced CT alone in 27 patients with 
NSCLC. They found that PET/CT resulted in more accurate 
staging, when using histopathological results as the 
reference standard, than either PET or CT alone. A study by 
Keidar and co-workers46 also looked at NSCLC recurrence. 
The specificity and positive predictive values of PET/CT, 
82% and 89%, were much better than with PET (interpreted 
with CT reports), which were only 53% and 75% 
respectively. Stand-alone PET has already proven to be 
significantly more accurate than CT for staging NSCLC47 
and to have a high impact on patient management48. The 
further improvement in the diagnostic accuracy of PET/CT 
makes a compelling case for this technology to be used as 
the primary non-invasive staging tool for evaluation of 
patients with lung cancer. This is particularly relevant 
following treatment where distortion of normal anatomy 
and tissue function as a result of therapeutic intervention 
can render interpretation of both CT, and to some extent 
PET, difficult. 
In addition to the increasing evidence for the 
effectiveness of PET/CT for NSCLC, there is emerging 
data  for  small  cell  lung cancer (SCLC). Malamitsi and 
co-workers49 examined the role of PET/CT in the successful 
staging, restaging and management of SCLC and NSCLC 
in 20 patients (21 studies). Successful diagnosis was 
achieved  in 16 studies and they concluded that in their 
early experience, PET/CT contributed significantly to 
correct  staging  and management. A recent study by 
Fischer et al50 was concerned with the response evaluation 
of 20 patients after chemotherapy and attempted to 
prospectively assess the feasibility of PET/CT for this 
purpose. They found that PET/CT was indeed feasible for 
chemotherapy response evaluation, and that FDG uptake 
significantly correlates with size changes as measured by 
CT. However, it is unclear as to whether or not there is any 
considerable benefit of using PET/CT as opposed to CT 
alone. 
 
Head and neck cancers 
PET/CT is of particular relevance to the evaluation of 
head and neck cancers and recurrent tumours by providing 
both anatomical and metabolic information. Although a 
structurally complex region of the body, traditional 
anatomical imaging modalities such as CT and MRI can 
result in poor specificity51. PET has a distinct advantage in 
being able to identify metabolic changes in the tumour, 
which precede morphologic changes after therapy or 
surgery. However, the PET images are limited by the lack 
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of anatomical detail51,52 and the complex patterns of normal 
physiological uptake. 
Schöder et al51 report that in a study group of 68 
patients with 157 foci displaying abnormal FDG uptake, 
there were 53% less equivocal lesions with PET/CT 
compared with PET alone. Furthermore, six confirmed 
malignancies were completely missed with PET, compared 
with only one for PET/CT. Zimmer et al53 discovered 
recurrence of thyroid carcinoma in four out of eight patients 
undergoing PET/CT that was otherwise undetectable. In a 
prospective study, Schöder et al54 studied 31 patients with 
oral cancer who demonstrated no evidence of lymph node 
metastases by clinical examination or conventional imaging 
(CT or MRI). The findings revealed a relatively high 
number of false-positive findings (6 out of 142) for PET/CT 
and the authors conclude that despite a reasonably high 
overall accuracy its clinical application may be limited.  
Schwartz et al55 investigated the role of PET/CT in pre-
radiotherapy staging of head and neck cancers in 20 
patients. It was found that PET/CT yielded a sensitivity and 
specificity of 96% and 98.5% respectively, and that 
imaging correlation with pathology was far better for 
PET/CT than for CT alone. 
The advantage of PET/CT in evaluation of head and 
neck cancers is the exact localization of FDG uptake to 
anatomic and pathologic structures. As Goerres et al56 
identified, edema of the neck shortly after treatment can 
introduce difficulties in clinical evaluation as most imaging 
modalities are unable to clearly differentiate between 
scarring and residual cancer. Zimmer et al53, Goerres et al56 
and Fukui et al57 all suggest that PET/CT will help in the 
localization of FDG uptake and therefore facilitate targeted 
biopsies of treatment sites, allowing earlier diagnosis of 
recurrence. A recent study found that PET/CT has a high 
impact on clinical management decisions in both staging 
and restaging settings58. This study also demonstrated that 
patients with positive and negative scans had significantly 
different survival suggesting an important role in prognostic 
stratification and use of PET/CT to select patients for more 
aggressive salvage therapies. 
 
Gastrointestinal cancers 
Rosenbaum et al59 provide a comprehensive overview 
of the use of PET, CT and PET/CT in relation to 
gastrointestinal tumours. Schöder et al60 similarly review 
the field and conclude that PET/CT adds diagnostic benefit 
in 30-40% of patients compared with PET alone. 
Wechalekar et al61 also discuss the advantages of PET/CT 
and review its applications to various cancers, including 
those of the gastrointestinal tract. 
A  study  conducted  by Antoch et al62 demonstrated 
the response of proven gastrointestinal stromal tumours 
(GIST) to imatinib (an anti-cancer drug marketed by 
Novartis™)  therapy.  The  number  of  lesions  detected   
in 20 patients was 135 for PET, 249 for CT, 279 for side-
by-side viewing and 282 for PET/CT. The authors 
concluded that PET/CT revealed more metastases from 
GIST than any other modality and correctly characterised 
the response to imatinib therapy in more patients. Goerres 
et al63 supported this conclusion and also showed that 
PET/CT is superior in assessing response to imatinib 
therapy. 
 
Colorectal cancer 
The application of PET/CT in colorectal tumours has 
seen the staging and restaging accuracy improve from 78% 
to 89% compared to PET alone and reduced the number of 
equivocal lesion diagnosis by 50%64. In the detection of 
post-operative recurrence of colorectal cancer in the pelvis, 
Even-Sapir et al65 have shown the improved diagnostic 
performance of PET/CT over PET alone. With 62 patients, 
the accuracy of PET/CT compared to PET alone was 93% 
and 74% respectively.  
 
Gynaecological tumours 
Several studies reveal an increase in metastatic 
diagnosis for gynaecological tumours, including ovarian, 
cervical, vulvar, vaginal and endometrial cancer, when 
using PET/CT compared with PET or CT alone66,67,68,69. 
Makhija et al70 used PET/CT to identify recurrence in eight 
patients, all with positive histology and seven with negative 
CT scans. This earlier detection by PET/CT avoided the 
morbidity and expense of ‘second-look’ laparotomy. 
Grisaru and co-workers72 compared PET/CT with 
conventional imaging techniques (CT, MRI and ultrasound) 
in 53 patients with gynaecological malignancies. PET/CT 
correctly identified all metastatic sites in nine of the 18 
patients (50%) undergoing initial staging (with no false 
positives), while conventional imaging identified metastatic 
spread in only 39% of patients (two of which were 
inconclusive). Furthermore, conventional imaging resulted 
in a 28% false positive rate. In patients studied for 
recurrence, PET/CT correctly identified recurrence or 
metastatic disease in 16 patients in whom recurrence had 
not been detected with conventional imaging techniques. 
PET/CT was false positive in one case and false negative in 
another. Wahl72 identified that PET/CT accurately assessed 
the presence of recurrent ovarian carcinoma in 81% of 
patients (N=22) in which a CT scan was negative or 
equivocal.  
Simcock et al73, in a prospective study involving 56 
patients with recurrent ovarian cancer, found that PET/CT 
showed less disease in 9% of cases, more disease in 52% of 
cases, and ultimately led to a major change of management 
plan in 58% of patients compared with conventional 
imaging (predominantly CT). Within this group, PET/CT 
also found a subset of patients with apparently localised 
disease or no definite evidence of disease. This result 
suggests that PET/CT can offer prognostic information 
along with disease localisation. This group showed 
improved survival compared with the patients with 
systematic disease. 
 
Breast cancer 
A review of early studies was provided by Zangheri et 
al74. In a subsequent retrospective study of 75 patients, 
PET/CT was found to add incremental diagnostic 
confidence in more than 50% of patients with FDG uptake 
abnormality on PET and accurately detected more regions 
involved by malignancy than did CT75. Recent studies have 
demonstrated that the metabolic characteristics of lytic and 
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sclerotic bone metastases differ significantly, particularly 
during therapy76. The ability to demonstrate bone 
architecture on CT and directly correlate this with 
metabolic signal is likely to improve the sensitivity and 
specificity of staging and therapeutic response assessment 
of metastatic bone disease in breast cancer patients and to 
complement the capability of PET to detect local, nodal and 
soft tissue disease deposits and evaluate their response to 
treatment77. In a recent study in patients with breast cancer 
and rising tumour markers, PET/CT had a higher sensitivity 
(85% vs 70%), specificity (76% vs 47%), and accuracy 
(81% vs 59%) compared to CT for the diagnosis of tumour 
recurrence78. PET/CT led to changes in the subsequent 
clinical management of 51% of these patients.  
 
Prostate cancer 
The radiopharmaceutical FDG when used in PET/CT 
has suboptimal sensitivity in the diagnosis of some cancers, 
i.e. prostate cancer, neuroendocrine tumours and primitive 
hepatic tumours due to relatively poor FDG avidity in these 
tumours. These generally slow growing tumours do not 
show a significant increased FDG uptake and 
immunohistochemistry studies have demonstrated that 
these tumours often have relatively low levels of Glut-1, the 
most important glucose transporter in many other FDG avid 
cancers. Inflammation and cancer are not clearly 
distinguishable as both processes are characterised by 
increased glucose metabolism79. Reske and co-workers80 
have investigated the use of 11C-Choline as the 
radiopharmaceutical for imaging prostate cancer in 
PET/CT. The results of the study show that 11C-Choline 
PET/CT identifies substantial tumour volumes within the 
prostate gland in 100% of patients examined. Similar 
results were also reported by Kwee81 using a dual-phase 
18F-fluorocholine PET technique. Reske80 found some 
overlap of 11C-Choline uptake in areas of the prostate with 
benign lesions and those with malignancies, leading to an 
unreliable localisation of the tumour in one of 26 of the 
patients. It was also found that some small tumour lesions 
hidden within normal tissue were missed in the study. 
However, it was suggested that this was due to the 
resolution of the PET/CT scanner used and that combined 
with determining the major malignant tumour, this is of 
small concern80.  
 
Hodgkin’s disease and non-Hodgkin’s lymphoma 
Hodgkin’s disease (HD) and non-Hodgkin’s lymphoma 
(NHL) are malignant neoplasms of the lymphoid tissue. 
They constitute less than 8% of all malignancies but this 
has been rising by several percent in the last few years82. 
Studies are beginning to emerge which indicate the 
usefulness of PET/CT, as opposed to PET or CT alone, in 
the diagnosis of varying tumours, including the 
management of lymphomas44,83,84,85,86. Rodriguez-Vigil et 
al87 found that PET/CT improved the overall sensitivity and 
specificity compared to PET or CT alone, and that PET/CT 
is more than suitable for staging, assessment of early 
response to therapy, restaging and follow-up of HD and 
NHL, ultimately improving the clinical management of 
patients. Schaefer et al88 retrospectively compared PET/CT 
with contrast-enhanced CT in 60 patients with either HD or 
NHL who required staging/restaging. It was found that 
sensitivity and specificity for staging and restaging with 
PET/CT were 94% and 100% respectively, compared to 
88% and 86% respectively for CT alone. Again it was 
found that PET/CT was sufficient for staging and restaging 
lymphomas, however studies are limited and further work 
is required to confirm these findings.  Freudenberg et al89 
found for patients with lymphoma a sensitivity of 78% for 
CT alone, 86% for PET alone, 93% for CT and PET read 
side by side, and 93% for combined PET/CT imaging. 
Combined imaging clearly has increased sensitivity 
compared with either PET or CT alone. 
 
Vertebral metastases 
Detection of vertebral metastases is important in 
clinical practice due to their potential for causing 
neurological complications. MRI is generally the preferred 
methodology for this purpose but some patients have either 
contra-indications or cannot tolerate this type of scan. 
Metser and co-workers90 have evaluated the role of PET/CT 
in the diagnosis of vertebral metastases in 242 lesions in 51 
patients. Analysis of the data suggested that PET/CT 
increased specificity in lesion detection compared with PET 
or CT alone. PET/CT was more accurate in defining the 
vertebral level of disease and the part of the vertebra 
involved. In one third of the patients it was possible to more 
accurately identify the level of soft tissue involvement. 
Thus, PET/CT may be a worthwhile alternative for 
evaluation of suspected vertebral metastases in patients 
unsuitable for MRI or in whom the MRI findings are 
equivocal due to prior treatment changes. 
 
Carcinoma of unknown primary 
PET/CT is also having more success in detecting occult 
primary tumours than PET, CT, or PET and CT side by 
side. Gutzeit et al91 in a study of 45 patients with an 
unknown primary tumour reported that PET/CT 
successfully detected more primary tumours than 
conventional modalities. Although the authors state that the 
majority of tumours remain occult whichever method is 
used. The presentation of patients with suspected recurrent 
disease while showing negative signs from conventional 
imaging is a common occurrence in oncology. Israel and 
co-workers92 have examined 36 patients in this situation 
using PET/CT and PET alone and found that PET/CT is 
more accurate than PET alone, but particularly with regard 
to specificity on a site based analysis, 97% compared to 
50%. Sensitivities were similar, suggesting that the main 
strength of PET/CT in this situation is the avoidance of 
false-positive interpretations of areas of FDG activity92. 
 
Patient management 
A significant outcome from the majority of studies, 
independent of the type of cancer assessed, is the change in 
patient management.  The accurate staging of tumours and 
the early detection of recurrence following therapeutic 
intervention reduce unnecessary treatment. In addition to 
the cost reduction, the patient avoids unpleasant and 
unnecessary side effects associated with prolonged 
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treatment. Changes to patient management have been 
discussed in relation to cancer types in the literature.  For 
example, Antoch et al45 and Keidar et al46 both report 
changes in patient management as a result of PET/CT for 
lung cancer.  King et al93 reports a 30% change in patient 
management for gynaecological tumours. Schöder et al51 
revealed altered patient care in 18% of patients with head 
and neck cancer. 
Bar-Shalom44 looked at 204 patients with 586 sites 
suggestive of malignancy. It was found that PET/CT 
provided additional value in 49% of patients in 30% (178) 
of sites. The principal benefit was accurate localisation of 
the PET metabolic information with the anatomical 
information from CT. The modified interpretation of the 
178 sites was found to be accurate in 95% of the cases, with 
a diagnostic error of 1.4% for all sites evaluated. PET/CT 
induced six false positive and three false-negative 
interpretations. The study concluded that PET/CT affected 
the clinical management of 14% of patients. Changes made 
included additional diagnostic assessment and decisions for 
the appropriate treatment and protocol. 
 
Treatment planning 
PET/CT has the potential to make a positive impact in 
radiotherapy treatment planning in three different ways: i) 
through more accurate staging, ii) through more accurate 
gross tumour volume (GTV) definition, and iii) by enabling 
explicitly non-uniform dose prescription with the target 
volume to maximise probability of local control for a fixed 
integral dose.  
 
Staging 
Improved patient selection and staging for radical 
radiotherapy using PET/CT will have a significant 
beneficial effect94. It is therefore important to separate the 
effects of improved patient selection and nodal staging 
from changes in GTV localisation when reporting the effect 
of PET on radiotherapy outcomes. Large reported changes 
in delineated target volume are sometimes the result of 
inclusion of nodal regions in the GTV and are therefore 
essentially changes in stage rather then tumour delineation 
per se. It is likely that the largest impact that PET/CT will 
have on radiotherapy outcomes will be through the 
provision of more accurate staging information as has 
already been demonstrated for stand-alone PET95. 
 
GTV definition 
There have been a number of studies showing the effect 
of PET/CT on GTV and planning target volumes (PTV) 
definition96,97,98,99,100,101. Ciernik and co-workers96 
investigated the use of PET/CT compared with standard CT 
to conduct treatment planning on 39 patients, 12 of whom 
were head and neck, 6 were lung cancer and the remaining 
21 were cancer of the pelvis. They found that significant 
changes  were  suggested  by  PET/CT in the GTV and 
PTV definitions. In 56% of all cases, the GTV was changed 
by  more  than 25% from PET/CT planning compared to 
CT based volume definition. Gondi et al100 studied 30 
patients, 16 of which had oesophageal cancer and 14 with 
NSCLC. They  employed  a  conformality index to quantify 
differences in the GTV definitions obtained by using CT 
alone and using the combined PET/CT. Their method 
accounts for size differences as well as three-dimensional 
overlap of the GTVs. Their results concur with others in 
suggesting that PET/CT significantly alters the definition of 
the GTV in radiotherapy planning.  
Improvements in identifying primary lesions, lymph 
node involvement and metastases, along with the accurate 
definition of these volumes by the use of PET/CT has seen 
the technique introduced to intensity-modulated 
radiotherapy (IMRT). The use of PET/CT guided IMRT for 
the treatment of head and neck tumours has been 
investigated by Wang et al102 and Paulino et al97. The 
benefit of using IMRT is that it allows a high dose of 
radiation to be delivered to the PTV and high risk disease 
regions, while irradiation of surrounding critical tissue 
regions such as the parotid glands, spinal cord, mandible, 
orbits, optic chiasm and brain is minimised. In the 26 
patient study presented by Wang et al102 they found that 
PET/CT changed initial CT based staging in 57% of cases. 
Volume analysis revealed that the PET/CT based GTVs 
were significantly different from those contoured from the 
CT scans alone in 14 of the 16 cases. Primary tumours in 8 
patients were poorly defined or not identified by CT images 
alone. In addition, 16 of 28 patients who were followed for 
more than 6 months with a median time of 17 months did 
not have any evidence of recurrence. In the study by 
Paulino et al97, a total of 40 patients with squamous cell 
carcinoma arising in the head and neck were treated using 
the IMRT technique. A comparison between PET/CT–GTV 
and CT–GTV was performed resulting in approximately 
25% of patients having their PET/CT–GTV underdosed 
when the CT–GTV was used for IMRT planning. However, 
these finding are not conclusive, as it is well documented 
that GTV delineation in the head and neck region can be 
difficult because certain normal areas can be FDG avid, 
such as the tonsils, base of tongue, muscles of mastication, 
thyroid gland and parotid glands93,98. 
One of the key technical questions is exactly how to 
use PET for GTV delineation. A range of different 
techniques have been reported for contouring, ranging from 
a simple visual interpretation in conjunction with an 
experienced nuclear medicine physician to a threshold 
method to distinguish between benign and malignant 
tumour. Gondi et al100 and Heron et al101 normalize PET/CT 
images using FDG uptake in the liver. Ciernik et al96 and 
Paulino et al97 advocate an intensity level of 50% of the 
maximum standardised uptake value (SUV) in the tumour 
to delineate the borders of the PET/CT GTV. Other groups 
employed the same threshold method, but with a 40% SUV 
uptake value103. A further method of autocontouring, which 
uses an SUV threshold value of 2.5 relative to the normal 
tissue intensity (which is generally regarded as the 
threshold for the distinction between benign and malignant 
lesions), has been suggested by Paulino and Johnstone97. 
Ashamalla et al98,99 have refined this method by contouring 
using a method they termed anatomic biological contouring 
(ABC). They observed a distinct “halo” around areas of 
maximum  SUV uptake. This method resulted in an SUV of  
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2.0 ± 0.4, very similar to the original value of 2.5.  
A common problem with all these techniques is that the 
optimum threshold depends on lesion size104. Studies are 
needed comparing histopathology with uptake for each 
treatment site and each tracer to properly validate any of 
these delineation methods. Nestle et al105 highlight the fact 
that all the above delineation methods result in substantially 
different volumes for non-small-cell lung cancer (NSCLC), 
concluding that “ … no method of automatic delineation of 
FDG positive tissue can be regarded as a reliable standard 
”. Grégoire et al106 come to a similar conclusion: “… fixed 
threshold-based methods are definitely not adequate for 
accurately segmenting head and neck tumours and should 
therefore be avoided”. Having pointed out the current 
limitations, Nestle et al105 do however make a number of 
sensible pragmatic recommendations, such as the use of 
well defined protocols for image acquisition, attenuation 
correction, reconstruction and then windowing and 
segmentation, emphasising that these should be quality 
controlled using phantom measurements. Riegel et al107 and 
Ciernik et al96 also report the need for GTV delineation 
protocols in treatment planning using PET/CT and highlight 
the large variations in delineation of the GTV using 
PET/CT that results if such protocols are not followed. In 
the absence of objective clinical evidence showing the 
effect of any particular PET contouring method, the best 
available method to date is visual contouring by a radiation 
oncologist in cooperation with a nuclear medicine 
specialist, following a well-defined protocol105. 
 
Non-uniform dose prescription 
Current radiotherapy practise implicitly assumes 
uniform spatial radiosensivity and clonogen density 
distributions throughout the delineated GTV by prescribing 
a uniform dose. In the absence of further information this is 
a reasonable assumption and is the basis of clinical 
experience to date. However, PET provides us with 
information about the heterogeneity of biochemical 
function within tumours. To obtain the maximum clinical 
benefit from this information, explicitly non-uniform dose 
prescriptions may be beneficial108 that, for example, boost 
dose to regions of intense FDG uptake. The feasibility of 
using IMRT to selectively boost dose to known regions of 
hypoxia has been demonstrated109, but significant further 
research is required before such techniques can be widely 
clinically implemented. Vanderstraeten et al110 highlight the 
need for trials, stating that “the hypothesis that tumour 
regions with the highest FDG uptake are most radioresistant 
can only be confirmed by clinical results”. Predictive 
radiobiological models of treatment outcome that explicitly 
include heterogeneity in biochemical function, validated 
using clinical trial outcomes, would be the ideal tool for 
assisting treatment planning. These could be built into 
IMRT optimisation functions, although we are not yet at 
this stage. 
 
Applications external to the field of oncology 
Presently, numerous applications of PET/CT exist that 
are external to oncology that, particularly with the advent of 
novel tracers, are predicted to broaden and be of 
increasingly widespread use111. This is reflected in recent 
literature, incorporating cardiology, neurology, psychiatry, 
infection and inflammation. The future applications of 
PET/CT are likely to be quite diverse. A 16 slice (and, less 
preferably, a 4 or 8 slice) scanner is sufficient for oncology 
but cardiology, for instance, requires at least 16-slice and 
preferably 64-slice PET/CT. Recent design improvements 
in PET components allow for 4 mm spatial resolution over 
a large field of view; 64 section CT scanners are currently 
being introduced and 128 or 256 section CT is likely to be 
the next standard – the combination of which would allow 
for imaging of the entire brain or heart without table 
movement112. Such progress increases the applicability of 
PET/CT. 
There is pronounced accumulation of FDG in activated 
macrophages and granulocytes associated with 
inflammation that facilitate imaging with FDG PET/CT. 
The capacity of FDG PET to identify infection or 
inflammation has been shown for various diseases such as 
pneumonia113, tuberculosis114, inflammation of mammary 
glands115, muscle tissue116 and sinuses117, lymph nodes118 
and abscesses119. Crymes et al120 provide a review of 273 
cases of apparent musculoskeletal infection investigated 
with FDG PET that show it to be a highly sensitive and 
specific mode of evaluation – a result reflected recently by 
Stumpe et al121. Keider et al122 used FDG PET/CT to 
investigate inflammation of bone marrow of the foot (that 
affects 15% of diabetes sufferers) and found that PET/CT 
allowed precise diagnosis of osteomyelitis versus soft-
tissue infection through better anatomic localisation of 
abnormal PET findings. Schiesser et al123 used PET/CT as 
part of a study undertaken in 2002, showing that it is a 
sensitive and specific method for the detection of infectious 
foci resulting from metallic implants in patients with 
trauma. PET/CT has also been shown to have advantages in 
the diagnosis of patients with fever of unknown origin124. 
Labelling of plastic microspheres with gamma emitting 
isotopes allows study of myocardial blood flow (MBF) via 
PET. Kaufmann and Camici125 show that cardiac PET with 
13NH3 or H215O is a robust and reproducible technique to 
obtain measurements of MBF and coronary flow reserve in 
vivo, and state that it is the “gold standard” against which 
new modes should be tested. CT has the capacity to 
complement this information with detailed anatomical data, 
and indeed Koepfli et al126 employed a hybrid PET/CT 
scanner to measure MBF with accuracy. Lodge et al127 
highlight the advantage of hybrid PET/CT systems in terms 
of the simultaneous acquisition of anatomical and 
physiological information, and discuss recent technological 
developments that allow study of impaired regional 
coronary blood flow reserve and absolute MBF 
quantification. Schwaiger et al128 found that PET/CT is a 
very promising technique for characterisation of coronary 
artery disease, particularly given the rapid improvement of 
CT slice technology, with the future use of PET/CT in 
cardiology largely being determined by cost and product 
availability, as well as patient referral patterns. In a study of 
FDG uptake in the thoracic aortic wall, Tatsumi et al129 
employed PET/CT and found that FDG uptake is located in 
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areas of metabolic activity of atherosclerotic changes and is 
distinct from aortic wall calcification. Wagner et al130 found 
that there is potential for PET/CT as applied to 
characterisation of angiogenesis directed molecular 
intervention in vivo.  
Such contemporary use is evidence of the suitability of 
PET/CT to studies within the areas of cardiology, infection 
and inflammation, and there are indications that further 
applications outside the field of oncology are likely to 
expand in the near future. While the applicability of 
PET/CT is increasing, it is likely that different 
configurations may be appropriate for differing PET/CT 
applications, rather than a single universally applicable 
design131. 
 
 
Conclusions 
 
Despite the introduction of artefacts which are 
additional to those of PET and CT scanning as single 
imaging modalities, there are significant advantages 
associated with the combined PET/CT scanner, including 
the use of the CT scan for attenuation correction and 
improved confidence in reporting the fused scans due to 
more accurate coregistration. The CT data is obtained in a 
matter of seconds compared with the more time intensive 
acquisition of a radionuclide transmission scan in 
conventional PET. This reduces imaging time per patient 
by up to 40%23, having a considerable effect on patient 
throughput. Another advantage of CT attenuation 
correction is that there is no longer a need for a radioactive 
transmission source. 
 
 
PET/CT has distinct benefits compared with other 
image fusion techniques based on software algorithms or 
visual co-registration. Misalignment due to patient 
movement is minimised by acquiring the PET and CT scans 
in one imaging session. This also overcomes issues 
associated with the time gap between the different image 
acquisitions for independent modalities, where pathological 
changes within the body may occur. 
PET/CT is a significant improvement over PET alone 
in its ability to define accurately the FDG anatomical 
uptake. Furthermore, the fused image has increased 
sensitivity compared with either individual scan. Some 
tumours are not particularly FDG avid and are therefore 
difficult to differentiate on a PET image.  New tracers may 
address this limitation. However, the CT scan may indicate 
some abnormality and by combining the two images there 
is a greater probability that the tumour will be correctly 
identified and localised.  In addition, in some cases there 
will be some normal physiological uptake of the radiotracer 
which may lead to false-positives on PET images.  
However, the CT scan allows identification of the uptake in 
normal tissue and improves specificity in the combined 
image. Overall, the combination of PET/CT improves 
diagnostic confidence and has been shown to have a 
significant effect on patient management. 
Hybrid imaging with PET/CT, SPECT/CT or PET/MRI 
is likely to become the modality of choice for many disease 
scenarios and will act as a stimulus for further research and 
development in radiopharmaceuticals, leveraging the major 
theoretical advantages of the tracer principle to deliver 
more sensitive and more specific diagnoses. 
 
 
 
 
Table 1. The use and efficacy of PET/CT in the treatment of various types of cancers is indicated by the selected studies shown.  Only 
selected results are included to provide an indication of the conclusions from each study.  PET+CT is used as an abbreviation for PET 
and CT viewed side-by-side. Where the accuracy of PET/CT has been independently assessed (without comparison to conventional 
imaging modalities) the fourth column has been left blank. 
 
Study No. of patients Cancer 
Modalities compared with 
PET/CT Comments 
Small (SCLC) and non-small cell lung cancer (NSCLC) 
Lardinois et al43 
2003 
50 NSCLC PET, CT, PET+CT PET/CT provided additional 
information in 41% of 
patients compared with PET 
and CT viewed side by side.   
 
Bar-Shalom et al44 
2003 
204 lung cancer (n=64) 
GI tumours (n=34) 
lymphoma (n=33)  
breast cancer 
(n=13) 
head and neck 
(n=4) 
other cancers 
(n=56)   
PET, CT PET/CT provided additional 
information in 49% of 
patients compared with PET 
or CT. 
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Study No. of patients Cancer 
Modalities compared with 
PET/CT Comments 
Antoch et al45 
2003 27 NSCLC PET, contrast enhanced CT 
PET/CT resulted in a 
treatment change in 15% of 
patients compared with PET 
and in 19% of patients 
compared with CT.   
 
Keidar et al46 
2004 42 NSCLC  PET+CT 
PET/CT changed 
management in 29% of cases. 
 
Malamitsi et al49 
2006 20 SCLC and NSCLC  CT and bone scan, MRI 
PET/CT led to a change in 
management in 6 patients. 
 
Fischer et al50 
2006 20  SCLC PET, CT  
Response evaluation by 
PET/CT is feasible, but 
uncertain as to whether it 
adds further information. 
 
Brianzoni et al132 
2005 28 
NSCLC (n=17) 
SCLC (n=7) 
NHL (n=4) 
CT 
PET/CT images significantly 
altered volumes in 11 patients 
(44% as 3 patients were 
excluded from the study). 
 
Shim et al133 
2005 106 NSCLC CT  
PET/CT correctly staged 
disease 86% of the time, 
compared to 79% with stand 
alone CT. Sensitivity, 
specificity and accuracy for 
CT alone were 70%, 69% and 
69% respectively, while for 
PET/CT they were 85%, 84% 
and 84% respectively. 
 
Kim et al134 
2007 674 NSCLC  
On a per-person basis 
sensitivity, specificity and 
accuracy of PET/CT were 
61%, 96% and 86% 
respectively. On a per-nodal 
station basis they were 46%, 
98% and 92%. 
 
Head and neck (H&N) cancers 
Schöder et al51 
2004 
68 squamous cell 
carcinoma (n=52) 
unknown primary 
neck tumour (n=8)
recurrent thyroid 
carcinoma (n=8) 
PET Accuracy of PET/CT was 
96% compared with 90% for 
PET alone. Six malignancies 
were missed by PET and one 
by PET/CT.  Patient 
management changed in 18% 
of cases with PET/CT. 
 
Zimmer et al53 
2003 
8 suspected 
recurrence of 
thyroid cancer 
MRI, CT PET/CT identified recurrence 
in 4 patients who otherwise 
had undetectable disease. 
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Study No. of patients Cancer 
Modalities compared with 
PET/CT Comments 
Schöder et al54 
2006 
31 oral cancer   Relatively high number of 
false-positive findings (6 out 
of 142) for PET/CT. 
 
Schwartz et al55 
2005 
63 H&N squamous 
cell carcinoma 
Contrast-enhanced CT PET/CT detected 100% and 
96% of heminecks and nodal 
zones respectively. CT alone 
only detected 82% and 78%. 
 
Connell et al58 
2007 
76 primary H&N 
mucosal squamous 
cell carcinoma 
 
 PET/CT resulted in tumour 
classification alternation in 
34% of cases, a treatment 
change in 29% and an altered 
treatment response 
assessment in 43%. 
 
Ashamalla et al99 
2007 
25 H&N cancers CT Significant volume 
modification (≥25%) was 
seen in 17 of 25 patients 
(68%). Interobserver 
agreement increased with use 
of anatomic biological 
contouring (ABC). 
 
Reigel et al107 
2006 
16 SCC, NHL, 
melanoma, B-cell 
lymphoma 
 
CT Significant variation occurred 
across physicians’ PET/CT 
volumes demonstrating the 
need for delineation protocol.  
Near-significant variation 
occurred across physicians’ 
CT volumes. 
 
Ha et al135 
2006 
36 H&N squamous 
cell carcinoma 
CT, MRI Treatment plan confirmed in 
69% of cases and altered in 
31%. 6 patients in altered 
group had disease upstaged. 
 
Breen et al136 
2007 
10 H&N squamous 
cell carcinoma 
CT, contrast-enhanced CT No significant differences 
detected in outlined volumes 
between modalities. 
 
Murakami et al137 
2007 
23 H&N squamous 
cell carcinoma 
Endoscopy, CT, MRI Using conventional methods 
coupled with PET/CT 
improved lymph node staging 
(74% to 83%) for one 
observer and including SUV 
data improved results further 
(83% to 87%) for two 
observers.  
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Study No. of patients Cancer 
Modalities compared with 
PET/CT Comments 
Gastrointestinal Cancers 
Antoch et al62 
2004 
20 gastrointestinal 
stromal tumours 
(Imatinib therapy) 
PET, CT, PET+CT Assessment of correct 
identification of tumour 
response at various periods 
after therapy: 
1 mo - PET/CT 95%; 
PET+CT 90%; PET 85%;  
CT 44% 
3 mo - PET/CT, PET+ CT 
and PET all 100%; CT 60% 
6 mo - PET/CT, PET+CT, 
PET all 100%; CT 57%. 
 
Goerres et al63 
2004 
34 gastrointestinal 
stromal tumours 
(Imatinib therapy) 
 
PET, contrast enhanced CT PET/CT provided additional 
information to PET or CT 
alone. 
Israel et al138 
2005 
34 various tumour 
types 
 PET/CT found useful for 
assessing incidental focal 
uptake of FDG. 
 
Bar-Shalom  
et al139 
2005 
32 oesophageal 
cancer 
PET+CT PET/CT changed initial 
characterisation of lesion in 
22% of tumour sites and had 
better specificity and 
accuracy than PET and CT 
compared side-by-side (81% 
vs 59% and 90% vs 83% 
respectively). 
 
Colorectal Cancer 
Cohade et al64 
2003 
45 colorectal cancer PET Frequency of equivocal 
lesions reduced by 50% with 
PET/CT and definite lesion 
characterisation increased by 
30%. Overall correct staging 
increased from 78 to 89%.  
 
Even-Sapir et al65 
2004 
62 rectal cancer PET The accuracy for 
differentiating malignant 
from benign for PET/CT was 
93% compard with 74% for 
PET alone. 
 
Kim et al140 
2005 
51 mucinous 
adenocarcinoma 
(n=6) 
non-mucinous 
adenocarcinoma 
(n=41) 
unknown (n=4) 
PET, software fusion PET+CT On a patient basis, accuracy 
of staging for PET/CT was 
88% compared with 71% for 
PET alone. Image fusion of 
independently acquired PET 
and  CT  images  failed  in  8 
(24%) patients.   
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Study No. of patients Cancer 
Modalities compared with 
PET/CT Comments 
Veit-Haibach 
et al141 
2006 
47 colorectal cancer CT, PET+CT Of 50 lesions identified, 
PET/CT colonography 
correctly identified 37, 
PET+CT identified 32 and 
CT-alone, 26. PET/CT 
colonography affected 
therapeutic decisions in 4 
cases. 
 
Gynaecological Malignancies 
Makhija et al70 
2002 
8 primary ovarian 
(n=6) 
fallopian tube 
(n=2) 
CT 62% had recurrent disease 
based on correlative histology 
with a positive PET/CT and a 
negative CT. 
 
Grisaru et al71 
2004 
53 gynaecologic 
malignancies 
(ovary, cervix, 
uterus, vagina, 
vulva, tube, GTN 
[gestational 
trophoblastic 
neoplasia]) 
staging (n=18) 
suspected 
recurrence (n=35) 
 
CT, MRI, US PET/CT led to a sensitivity of 
97% compared with 40% for 
standard imaging and 
similarly a specificity of 94% 
compared with 40%, 
respectively. 
 
Wahl et al72 
2004 
22 epithelial ovarian 
cancer (n=22) 
CT On a patient basis, PET/CT 
had 81% accuracy.  Failure to 
detect  small  tumour  foci 
(<1 cm) was not uncommon. 
 
Simcock et al73 
2006 
56 recurrent ovarian 
cancer 
CT PET/CT altered the known 
disease distribution in 64% of 
studies, showing less disease 
in 9% and more disease in 
52%. A major change of 
patient management plan 
occurred with 58% of 
patients. 
 
Choi et al142 
2006 
22 cervical carcinoma MRI PET/CT shown to be more 
sensitive than MRI in the 
detection of lymph node 
metastases (57.6% compared 
with 30.3%). No significant 
differences found with regard 
to specificity or accuracy. 
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Study No. of patients Cancer 
Modalities compared with 
PET/CT Comments 
Breast cancer 
Tastumi et al86 
2006 
75 breast cancer PET, CT  PET/CT led to improved 
diagnostic confidence 
compared with PET in 30 out 
of 50 patients who exhibited 
increased FDG uptake.  
PET/CT accurately staged 
59/69 patients, whereas CT 
staged 53/69. 
 
Radan et al78 
2006 
46 breast cancer Contrast enhanced CT In 37 patients comparisons of 
PET/CT and contrast 
enhanced CT showed higher 
sensitivity (85% vs 70%), 
specificity (76% vs 47%) and 
accuracy (81% vs 59%) for 
PET/CT. 
 
Veit-Haibach  
et al143 
2007 
44 breast cancer PET, CT, PET+CT Overall tumour staging was 
correctly determined by 
PET/CT in 91% of cases, 
86% for PET+CT, and 82% 
for PET-alone and CT-alone. 
PET/CT changed therapy in 2 
cases compared to PET+CT, 
4 cases compared to PET 
alone and 5 cases compared 
to CT alone. 
 
Piperkova et al144 
2007 
49 breast cancer Contrast enhanced CT PET/CT analysis returned as 
many true-positive (TP) and 
true-negative (TN) as 
PET/CT + CE-CT, while CE-
CT alone returned 23 less TP 
lesions and 16 less TN 
lesions. PET/CT images had 
2 false-positive (FP) and 5 
false-negative (FN) findings, 
significantly better than CE-
CT alone (18FP & 28FN). 
PET-CT + CE-CT returned 
no FP results and 3 FNs. 
 
Prostate Cancer 
Reske et al80 
2006 
26 prostate cancer  PET/CT resulted in 100% 
true positive based on 
correlation with 
histopathologic results. 
 
Schmid et al145 
2005 
19 prostate cancer  
18F-fluorocholine (FCH) 
PET/CT determined to be 
effective in detecting 
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Study No. of patients Cancer 
Modalities compared with 
PET/CT Comments 
recurrence of disease or  
metastases based on 
histopathologic results. Not 
effective for T-staging of 
tumour; unable to 
differentiate between benign 
and malignant growths. 
 
Lymphoma 
Schaefer et al88 
2004 
60 HD and NHL Contrast enhanced CT Sensitivity and specificity for 
staging and restaging with 
PET/CT were 94% and 100% 
respectively, compared with 
88% and 86% respectively for 
CT alone. 
 
Raanani et al146 
2006 
103 HD (n=35) 
NHL (n=68) 
Contrast enhanced CT For NHL, 32% of patients 
changed disease staging and 
treatment approach was 
altered in 25% of cases for 
PET/CT. For HD, 47% of 
patients changed disease 
staging and treatment 
approach was altered in 45% 
of cases. 
 
Freudenberg  
et al89 
2004 
27 HD and NHL PET, CT, PET+CT On a patient basis, 
sensitivities for CT alone, 
PET alone, PET+CT and 
PET/CT respectively were 
78%, 86%, 93% and 93%. 
Patient based accuracies were 
67%, 93%, 96% and 96%. 
 
Vertebral metastases 
Metser et al90 
2004 
51 spinal lesions PET, CT PET/CT identified 242 
lesions (90% malignant), PET 
220 lesions, and CT 159 
lesions. On a patient basis, 
the sensitivity of PET/CT was 
98% and 74% for PET.  
Unknown tumours 
Gutzeit et al91 
2005 
45 unknown primary 
tumour 
 PET, CT, PET+CT PET/CT successfully detected 
more primary tumours than 
the other modalities, although 
not statistically significant. 
 
Israel et al92 
2004 
36 suspected occult 
recurrence 
PET PET/CT resulted in further 
management and treatment 
planning in 33% of patients. 
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